Results 61 to 70 of about 15,373 (177)

Oxaziridines: Versatile Reagents in Modern Organic Synthesis

The Chemical Record, EarlyView.
Being capable of transferring an O atom and N‐group/atom, oxaziridines are considered multitasking agents. These are employed for diverse organic transformations, such as epoxidation of olefins, α‐ and γ‐hydroxylation/amination of carbonyl compounds, oxidation of sulfides, [3+2]cycloaddition with unsaturated systems.
Ajeet Chandra, Subba Rao Cheekatla, Keshaba Nanda Parida   +2 more
wiley   +1 more source

Cost-effectiveness analysis of CDK4/6 inhibitors in the second-line treatment for HR+/HER2− advanced or metastatic breast cancer

Frontiers in Pharmacology
ObjectiveThe aim of this study was to compare the cost-effectiveness of various CDK4/6 inhibitors plus fulvestrant with fulvestrant monotherapy in the second-line treatment for patients with HR+/HER2− advanced or metastatic breast cancer from the Chinese
Kaixuan Wang, Shixian Liu, Shunping Li, Jie Gao   +3 more
doaj   +1 more source

Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer - A Chinese healthcare system perspective

Frontiers in Oncology, 2023
AimTo evaluate the cost-effectiveness of palbociclib plus fulvestrant in the second-line treatment of women with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer based on the latest published follow ...
Wentao Zhu, Miaomiao Zheng, Panpan Xia, Wanglong Hong, Guoqiang Ma, Aizong Shen, Aizong Shen   +6 more
doaj   +1 more source

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source

Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience

, 2021
Introduction: Fulvestrant has demonstrated efficacy in hormone receptor positive (HR+) metastatic breast cancer (mBC), both in first-and second-line settings. In clinical practice, however, fulvestrant has been used as a later-line therapy.
Duc Le, Shahid Ahmed, Philip Wright, Samitha Andrahennadi, Mita Manna, Amer Sami, Ali El-Gayed, Osama Ahmed, Kamal Haider, Haji Ibraheem Chalchal   +9 more
core   +1 more source

The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer

Current Oncology, 2022
Background: Palbociclib, a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, in combination with letrozole or fulvestrant has been demonstrated to prolong the progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human ...
Fulbert Fu, Jessica Kano, Julia Ma, Mera Guindy   +3 more
doaj   +1 more source

CDK4/6 Inhibitors in the Management of Hormone Receptor‐Positive (HR+)/Human Epidermal Growth Factor Receptor 2‐Negative (HER2−) Advanced Breast Cancer in Indonesia: Challenges, Opportunities, and Recommendations

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Evidence‐informed recommendations emphasize the integration of CDK4/6 inhibitors with endocrine therapy as a central component in the management of HR+/HER2− advanced breast cancer in Indonesia. Expanding access and facilitating integration within national treatment frameworks are crucial to improve outcomes and reduce disparities in care.
Sonar Soni Panigoro, Samuel J. Haryono, Prihantono Prihantono, Dedy Hermansyah, Sumadi Lukman Anwar, Yohana Azhar, Febriyanto Kurniawan, Putu Anda Tusta Adiputra, Kristanto Yuli Yarso, Asdi Wihandono   +9 more
wiley   +1 more source

Functional grouping of fulvestrant sensitivity genes.

, 2014
Functional grouping of fulvestrant sensitivity genes.
Anker Hansen (214769), Elizabeth Anderson (20931), Justin Lindemann (520673), Wiktor Mazin (118965), Irene Kuter (520674), Thomas Jensen (92927), Naomi Laing (520675), Steen Knudsen (858)   +7 more
core   +1 more source

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer [PDF]

, 2019
BackgroundFulvestrant, a selective estrogen receptor degrader, is approved for first- and second-line treatment of postmenopausal women with hormone receptor-positive advanced breast cancer (ABC).MethodsMeta-analysis of randomized controlled trials (RCTs)
Ellis, Matthew, Campbell, Christine, Di Leo, Angelo, Bradbury, Ian, Pritchard, Kathleen I., Ohno, Shinji, Robertson, John F. R., Jiang, Zefei   +7 more
core   +1 more source

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer

npj Breast Cancer, 2023
This clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with metastatic ER+/HER2− breast cancer (BC). Eligible patients were women with ECOG 0–2, ER+/HER2− measurable or evaluable metastatic BC. Prior fulvestrant was allowed.
Anthony D. Elias, Nicole S. Spoelstra, Alyse W. Staley, Sharon Sams, Lyndsey S. Crump, Gregory A. Vidal, Virginia F. Borges, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Angelo D’Alessandro, Kathryn L. Zolman, Adrie van Bokhoven, Yonghua Zhuang, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin III, Dexiang Gao, Jennifer K. Richer   +22 more
doaj   +1 more source